Production (Stage)
Brainstorm Cell Therapeutics Inc.
BCLI
$1.24
$0.1412.73%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 17.98% | -52.80% | -25.95% | -22.41% | -32.06% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 24.86% | -33.62% | -49.49% | -45.27% | -51.97% |
| Operating Income | -24.86% | 33.62% | 49.49% | 45.27% | 51.97% |
| Income Before Tax | 15.79% | 46.70% | -120.88% | 52.32% | 32.77% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 15.79% | 46.70% | -120.88% | 52.32% | 32.77% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 15.79% | 46.70% | -120.88% | 52.32% | 32.77% |
| EBIT | -24.86% | 33.62% | 49.49% | 45.27% | 51.97% |
| EBITDA | -26.02% | 33.81% | 49.93% | 45.78% | 52.60% |
| EPS Basic | 42.69% | 67.92% | -22.71% | 73.42% | 61.85% |
| Normalized Basic EPS | 42.70% | 67.92% | -22.76% | 73.42% | 61.85% |
| EPS Diluted | 42.69% | 67.92% | -22.71% | 73.42% | 62.48% |
| Normalized Diluted EPS | 42.70% | 67.92% | -22.76% | 73.42% | 61.85% |
| Average Basic Shares Outstanding | 46.95% | 66.14% | 79.99% | 79.40% | 76.23% |
| Average Diluted Shares Outstanding | 46.95% | 66.14% | 79.99% | 79.40% | 76.23% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |